INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
Boca Raton, Florida, April 23, 2024 -- INmune Bio, Inc. , a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight...
Source: marketscreener.com